Navigation Links
Wyeth Reports Earnings Results for the 2009 Second Quarter and First Half and Raises Full Year 2009 Guidance
Date:7/23/2009

ered in isolation or as a substitute for the results of operations and diluted earnings per share prepared in accordance with GAAP.

(4) The following table presents worldwide net revenue by reportable segment, together with the percentage changes from the comparable periods in the prior year, as reported and excluding the impact of foreign exchange (FX):

                                              (UNAUDITED)
                     --------------------------------------------------------
                     Three Months Ended 6/30/2009  Six Months Ended 6/30/2009
                     ----------------------------  --------------------------

    Net Revenue by                     Increase                      Increase
    Reportable       $ in              Excluding   $ in              Excluding
    Segment          Millions Decrease   FX        Millions Decrease   FX
    --------------   -------- -------- --------    -------- -------- ---------

    Pharmaceuticals   $4,779    (4)%     3%        $9,267     (5)%      2%
    Consumer
     Healthcare          631    (5)%     2%         1,244     (7)%      -
    Animal Health        285    (9)%     1%           561     (5)%      6%
                      ------ ------  ------        ------  ------   ------
    Consolidated
     Total            $5,695    (4)%     2%       $11,072     (5)%      2%
                      ====== ======  ======        ======  ======   ======


Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

<
'/>"/>
SOURCE Wyeth
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. Wyeth Announces Results of the Companys Offer Relating to Holder Right to Surrender Convertible Debentures
2. Wyeth Consumer Healthcare Announces the Availability of New Centrum Ultra Line of Multivitamins Specially Formulated For Women and Men
3. Wyeths Prevenar 13* Receives First Approval
4. Wyeth Pharmaceuticals and Catalyst Biosciences Announce Agreement to Develop and Commercialize Factor VIIa Products
5. Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders
6. New Therapies, Including Novel Biologic Agents from Elan/Wyeth and Eli Lilly, Will Drive Robust 11 Percent Annual Growth In the Alzheimers Disease Market
7. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project
8. DIA 45th Annual Meeting Features Sessions Highlighting Wyeth v. Levine and Pandemic Influenza
9. Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care
10. U.S. and 16 States Join Suits Against Pharmaceutical Giant, Wyeth
11. Wyeth Reports Earnings Results for the 2009 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... MMAR Medical is pleased to announce their ... regular customers to enjoy several perks and benefits when ... wholesale license. It’s a great choice for independent athletes, ... who regularly purchase medical braces but could use a ... active lifestyle or those of your club, group or ...
(Date:8/28/2014)... The need for larger space has become more ... The new location - 4700 Bryant Irvin Court, Fort Worth, ... space than TLC had in the past, as well as ... our new location because it represents a good fit for ... in size compared to the current one, the building itself ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 Aeroflow ... to acquire as part of a strategic expansion ... is positioned for taking ownership of new businesses ... increase economies of scale. , Last week, the ... with Hometown Respiratory to increase service in the ...
(Date:8/27/2014)... 2014 According to a new market ... Market (Neurosurgical Navigation Systems, ENT Navigation Systems and Orthopedic ... Trends and Forecast 2014 - 2020", the global surgical ... in 2013 and is expected to grow at a ... an estimated value of USD 295.5 million in 2020. ...
(Date:8/27/2014)... (PRWEB) August 28, 2014 DiaSorin has ... Utility of 1,25 Dihydroxyvitamin D,” will feature guest speaker ... Penny George Institute for Health and Healing Integrative Medicine. ... the Penny George Institute for Health and Healing and ... Health Care, Minneapolis, Minnesota. He also serves as a ...
Breaking Medicine News(10 mins):Health News:MMAR Medical Announces Customer Membership Program 2Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Health News:Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 2Health News:DiaSorin Announces New Webinar in Their Annual Vitamin D Series 3
... gives new meaning to the word transformative, researchers from ... are integrating some of the best practices of industry ... propel the development of innovative cancer treatments from the ... Cancer Center has initiated the Translational Research Acceleration Collaboration ...
... Foundation for a,Healthy Florida, the philanthropic affiliate of ... approved $951,486 in grants to be awarded this,winter ... needs in their communities., "The Blue Foundation ... to quality health-related services for Floridians who are ...
... lives could be,saved over the next five years through ... the 30 hardest hit countries in,Africa, according to a ... rapid scale-up would increase annual economic output,by as much ... cases, and,free up 427,000 needed hospital beds over five ...
... MIAMI, Jan. 25 OPKO Health, Inc. (Amex: ... and Richard C.,Pfenniger, Jr. to its Board of Directors. ... David Eichler. Mr. Pfenniger was,appointed to fill the vacancy ... a newly created Board position., "The addition of ...
... Calif., Jan. 25 IPC The,Hospitalist Company, Inc. (Nasdaq: ... yesterday the initial public offering of 5,200,000,shares of its ... $16.00 per share.,The Company has agreed to sell 3,300,000 ... to sell the remaining 1,900,000 shares of,common stock. The ...
... as 30,000 deaths each year, study says , , FRIDAY, ... greatly reduce their risk of developing ovarian cancer, and the ... study confirms. , The use of oral contraceptives has long ... The authors of the new study say their findings show ...
Cached Medicine News:Health News:ITRAC on track and bridging gap between academic research and applied discovery 2Health News:ITRAC on track and bridging gap between academic research and applied discovery 3Health News:Eleven Florida Nonprofit Organizations to Receive Grants Totaling Nearly $1 Million From The Blue Foundation 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 2Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 3Health News:Global Health and Business Leaders Announce 36-Month Effort to Expand Malaria Control in Africa; 3.5 Million Lives Could be Saved in Five Years, Study Finds 4Health News:OPKO Health Announces Changes to Board of Directors 2Health News:OPKO Health Announces Changes to Board of Directors 3Health News:IPC The Hospitalist Company, Inc. Prices Initial Public Offering 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 2Health News:Oral Contraceptives Cut Ovarian Cancer Risk 3
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com announces ... in its catalogue: Global Orthopedic Soft ... http://www.reportlinker.com/p02316671/Global-Orthopedic-Soft-Tissue-Repair-Devices-Market-2014-2018.html About Orthopedic ... the mass of cells that connect, support, or ... soft tissues such as tendons, ligaments, cartilage, fascia, ...
(Date:8/27/2014)... 2014 Decision Resources Group finds that the ... Memphis health system and hospital sector in ... rivals Methodist Le Bonheur Healthcare and Baptist Memorial Health ... patient care. In addition, a national contract recently signed ... plan enrollment in the Memphis ...
(Date:8/27/2014)... , Aug. 27, 2014 Reportlinker.com ... available in its catalogue: Global Heart ... http://www.reportlinker.com/p02316644/Global-Heart-Valve-Repair-and-Replacement-Market-2014-2018.html About Heart ... in the human heart which control the flow ... affected with heart valve diseases such as valvular ...
Breaking Medicine Technology:Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 3Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018 5Memphis-area Health Systems Turn Attention to Clinical Integration 2Global Heart Valve Repair and Replacement Market 2014-2018 2Global Heart Valve Repair and Replacement Market 2014-2018 3Global Heart Valve Repair and Replacement Market 2014-2018 4
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
... on Smart Cards. Insert the card and turn ... turns itself off after the programmed time. The ... of treatments. Simply provide your patient with the ... progress on the next visit.,The initial set of ...
... battery operated dual-channel therapy system designed for use ... 4 Conti also includes a programme for treating ... 4 Conti provokes a contraction of the pelvic ... muscles need exercising. In URGE incontinence, ELPHA 4 ...
... disposable template is designed for ... eliminate the need for cleaning. ... premium silicone molded over a ... needle placement while maintaining needle ...
... is designed for use with the ... prostate brachytherapy. Please be sure that ... the graphics on the Reusable Template. ... from lower surface which fits into ...
Medicine Products: